Allarity Therapeutics, Inc. (ALLR) intrinsic value & 10-year financials
Allarity Therapeutics, Inc. (ALLR) has a Graham intrinsic value of $656.79 per share. At $0.89 on Oct 17, 2026, the stock trades 100% below that value. Over the last 7 fiscal years revenue shrank 71.7% a year to $320.0K, with an average return on invested capital of 957.5%.
- Graham intrinsic value
- $656.79
- Share price (Oct 17, 2026)
- $0.89
- Price vs Graham value
- 100% below
- Market cap
- $1.8M
- Revenue (FY2025)
- $320.0K
- Revenue growth (7-yr CAGR)
- -71.7%
- ROIC (10-yr avg)
- 957.5%
- Free cash flow (FY2025)
- -$14.8M
ALLR 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $320.0K | -$11.2M | — | -$14.8M | -3939.1% | -116.5% |
| FY2024 | $0 | -$24.5M | — | -$17.6M | — | 11662.7% |
| FY2023 | — | -$11.9M | -$10.26 | -$12.7M | — | -12594.9% |
| FY2022 | — | -$16.1M | -$2.21 | -$16.8M | — | 7058.6% |
| FY2021 | $50.0M | -$26.6M | -$4.19 | — | -53.1% | -230.8% |
| FY2020 | — | -$6.6M | — | -$7.3M | — | -34.1% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Allarity Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Allarity Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -15.3% ROIC.
Allarity Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Allarity Therapeutics, Inc. is modeled at -71.7% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $656.79 per share.